Circulating biomarker levels for diagnosis and risk-stratification of traumatic brain injury
AssigneeBrainbox Solutions, Inc.
InventorsDonna J. EDMONDS, Timothy E. VAN METER, NaZanin MIRSHAHI
Life of this patent
Estimating the term…
Abstract
Methods, compositions and kits useful in the diagnosis, prognosis and/or assessment of brain injuries and risk for brain injuries, such as hemorrhage, are based upon detection of certain biomarkers.
Claims20
(canceled)
A method of measuring the levels of biomarker proteins in a biological sample from a human patient that has or is suspected of having a brain injury, the method comprising:
- (a) measuring levels of biomarker proteins Neurogranin (NRGN) and Synuclein Beta (SNCB) in the biological sample;
- (b) detecting a changed level of NRGN, and a changed level of SNCB relative to reference levels;
- and
- (c) administering treatment for a brain injury when a changed level of NRGN and a changed level of the SNCB is detected.
A method of measuring the levels of biomarker proteins in a biological sample from a human patient that has or is suspected of having a brain injury, the method comprising:
- (a) measuring levels of the biomarker proteins Neurogranin (NRGN) and/or Neuron Specific Enolase (NSE), and Synuclein Beta (SNCB) in the biological sample;
- (b) detecting a changed level of:
- (i) NRGN and/or NSE relative to a respective reference level of NSE and/or NRGN;
- and
- (ii) SNCB relative to a reference level of SNCB;
- (c) comparing the changed level of NRGN and the changed level of SNCB relative to their respective reference levels in at least one classifier algorithm to identify the patient as having a high, medium, or low risk of brain injury;
- and
- (d) administering treatment for a brain injury when the patient has a high or medium risk of brain injury.
A method of measuring the levels of biomarker proteins in a biological sample from a human patient that has or is suspected of having a brain injury or neurodegenerative disease and treating the patient, the method comprising:
- (a) measuring levels of the biomarker proteins Neurogranin (NRGN) and/or Neuron Specific Enolase (NSE), and Synuclein Beta (SNCB) in the biological sample at a first time point and a second time point, respectively;
- (b) detecting a changed level of:
- (i) NRGN and/or NSE at the second time point relative to the level of NSE and/or NRGN at the first time point;
- and
- (ii) SNCB at the second time point relative to the reference level of SNCB at the first time point;
- (c) comparing the changed level of NRGN and/or NSE and the changed level of SNCB relative to their respective reference levels to identify the patient as having a high, medium, or low risk of brain injury when at least one of changed levels of NRGN and/or NSE, and the changed level of SNCB trend toward a changed brain injury status profile;
- and
- (d) administering treatment for a brain injury when the patient has a high or medium risk of brain injury or neurodegenerative disease.
Dependencies are inferred from the claim text.